MENQUADFI DIN 02507161
Status: Marketed
Holder: SANOFI VACCINES CANADA LTD.
Available to quote
Health Canada record
| Active ingredient(s) | MENINGOCOCCAL GROUP A POLYSACCHARIDE-TETANUS TOXOID CONJUGATE 10 MCG; MENINGOCOCCAL GROUP C POLYSACCHARIDE-TETANUS TOXOID CONJUGATE 10 MCG; MENINGOCOCCAL GROUP Y POLYSACCHARIDE-TETANUS TOXOID CONJUGATE 10 MCG; MENINGOCOCCAL GROUP W POLYSACCHARIDE-TETANUS TOXOID CONJUGATE 10 MCG; TETANUS TOXOID 55 MCG |
|---|---|
| Dosage form | Solution |
| Route | Intramuscular |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | J07AH08 MENINGOCOCCUS, A, C, Y, W-135, TETRAVAL. PURIFIED POLYSACC. ANTIGEN CONJUGATED |
| Original market date | 01-Apr-2025 |
| Current status date | 01-Apr-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
Sanofi Vaccines Canada Ltd. — licence 101420, currently licensed, last inspection rating C (2026-02-23).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 24522 | 2020-10-29 | New Drug Submission (NDS) |